Phosphatidic acid and muscle strength: the forgotten future of anabolism?
Every training session that ends in a squat rack, every eccentric contraction that leaves muscle fibers slightly torn, triggers not only mechanical damage but also a cascade of molecular signals that initiate repair and growth. At the heart of this cascade sits a lipid molecule most nutritionists have never heard of: phosphatidic acid (PA). Produced directly at the Z-lines of contracting muscle by the enzyme phospholipase D, PA has been identified as a direct activator of mTORC1 — the master regulator of muscle protein synthesis. Its story is one of genuine biological elegance, commercially exploited promise, and, ultimately, clinical ambiguity that deserves honest examination.
1. The muscle is not just a protein machine: mechanotransduction
For decades, the dominant model of muscle adaptation was protein-centric: consume adequate leucine, train hard, wait for mTOR to be activated by amino acids, and hypertrophy follows. This model is accurate but incomplete. Skeletal muscle also responds to mechanical force itself — independently of nutritional signals — through a process called mechanotransduction: the conversion of physical deformation into biochemical signals that drive gene expression, protein synthesis, and structural remodeling. The implications are substantial. A muscle fiber does not simply « feel » a load through calcium ions and ATP depletion; it reads the load through a sophisticated lipid-based signaling language in which phosphatidic acid plays a central role.
The Z-line — the transverse structural anchor of each sarcomere, the contractile unit of muscle — is not merely a passive scaffold. It is a mechanosensory node. When sarcomeres are stretched or loaded, the Z-line transmits force across the cytoskeleton and, critically, concentrates the enzymes that translate that force into lipid second messengers.
2. mTOR: the anabolic conductor — and PA’s pivotal role
mTORC1 integrates signals from amino acids, growth factors, energy status, and — crucially — mechanical stimuli to control the rate of ribosomal biogenesis and protein synthesis. Leucine activates it via the Rag GTPase pathway. IGF-1 and insulin activate it via PI3K/Akt. And phosphatidic acid activates it by a third, structurally distinct mechanism: direct binding to the FKBP12-rapamycin-binding (FRB) domain of mTOR, displacing the endogenous inhibitor DEPTOR and promoting mTORC1 assembly and activity.
3. Founding experimental evidence: PLD, PA, and mTOR activation by mechanical stretch
The mechanistic link between mechanical loading, phospholipase D, and mTOR was first established rigorously by Hornberger and colleagues in a landmark 2006 study in skeletal muscle. Using ex vivo passive stretch of isolated muscle preparations, they demonstrated that mechanical stimulation increases PLD1 and PLD2 activity specifically at the Z-lines, the sites of highest mechanical strain. This localized activation produces a transient pulse of PA that directly activates mTOR signaling — and, critically, this activation is blocked by pharmacological inhibition of PLD but not by rapamycin alone.
A complementary layer of regulation was described by You et al. in 2014, who demonstrated that diacylglycerol kinase zeta (DGKζ) also contributes to mTORC1 activation in loaded muscle. The broader framework of mechanotransduction and mTORC1 regulation was synthesized in a comprehensive review by Hornberger in 2011.
4. Human trials: promising but ambiguous
The most frequently cited positive trial is Hoffman et al. (2012), a double-blind, placebo-controlled study in 18 resistance-trained men supplementing with 750 mg/day of soy-derived PA over 8 weeks. The PA group showed a 12.7% increase in squat one-repetition maximum versus 9.3% in the placebo group, and a 2.6% gain in lean body mass versus 0.1% in controls.
The pivotal counterpoint is Gonzalez et al. (2016), which tested two PA doses against placebo in 28 resistance-trained men over 8 weeks. In the primary parametric statistical analysis, there was no significant group-by-time interaction for any outcome measure. A third study, Escalante et al. (2016), examined the commercial blend MaxxTOR® combining PA with leucine, HMB, and vitamin D3 and reported positive effects, but it is impossible to attribute benefits specifically to PA in such a combination.
The honest summary is: there is a plausible mechanistic basis for an effect, a pilot study suggesting benefit, and at least one adequately powered trial showing no statistically significant advantage over placebo in conventional analysis.
5. The Achilles heel: bioavailability of an oral phospholipid
Phospholipids are not efficiently absorbed intact from the gastrointestinal tract. The dominant pathway involves hydrolysis by phospholipase A2 in the intestinal lumen, which cleaves PA into lysophospholipids and free fatty acids before absorption. There is no guarantee that intact PA reaches the systemic circulation in quantities sufficient to influence intramuscular mTOR signaling. Commercial PA supplements are predominantly derived from soy lecithin via bacterial phospholipase D-mediated transphosphatidylation. The published trials have not included pharmacokinetic substudies to address this gap.
6. Galenic strategies to improve delivery: liposomes and nanoemulsions
Liposomal encapsulation (50–200 nm vesicles) and nanoemulsions are being explored to protect PA from premature hydrolysis and improve intact absorption. Both technologies are currently explored in lipid drug delivery more broadly. No published human trial has yet compared a liposomal or nanoemulsion PA formulation against conventional soy-PA using tissue-level mTOR activation as primary endpoints. The galenic promise remains ahead of the evidence.
7. Why an injectable form would be risky: the PI3K/Akt/mTOR axis and oncological concerns
The PI3K/Akt/mTOR pathway is one of the most frequently hyperactivated signaling cascades in human cancer. mTORC1 overactivation promotes tumor cell proliferation, survival, and resistance to apoptosis; mTOR inhibitors are licensed treatments for several cancers. Supplying exogenous PA systemically would risk creating a pharmacological environment favorable to tumor proliferation in any patient with latent neoplastic disease. An injectable PA preparation for anabolic purposes would administer a pan-tissue mTOR agonist with no selectivity for healthy muscle — its development is contraindicated by current mTOR biology.
8. The real path: amplifying endogenous PA through training and nutrition
The most compelling implication of the Hornberger mechanotransduction framework is that the production of PA within the muscle fiber is itself a modifiable physiological variable. High-load, compound movements with significant eccentric components generate the greatest Z-line strain and therefore the greatest PLD-mediated PA production. Tempo manipulation, progressive overload, and exercise selection are endogenous PA delivery systems — more targeted, more physiologically regulated, and entirely free of bioavailability constraints.
Nutritional strategies can amplify this endogenous signal. Adequate dietary phosphatidylcholine — present in egg yolks, liver, soy products, and many animal foods — provides substrate for PLD. Leucine acts synergistically with mechanically generated PA on mTORC1. Omega-3 fatty acids may modify membrane lipid composition to enhance PLD sensitivity. The strategic combination of high-mechanical-load training, sufficient dietary leucine (>2.5 g per meal), and phosphatidylcholine-rich foods maximizes endogenous PA production without the uncertainties of oral PA supplementation.
9. Phosphatidic acid in sarcopenia and rehabilitation: a research hypothesis worth pursuing
Beyond competitive athletics, the mechanotransduction/PA/mTOR axis carries genuine clinical interest in the context of sarcopenia — the progressive loss of muscle mass and strength accompanying aging and several chronic diseases. Sarcopenic muscle is characterized by reduced mTOR responsiveness to anabolic stimuli and mechanical loading (« anabolic resistance »). If PA supplementation could partially restore mTOR sensitivity in anabolic-resistant muscle, it would represent a genuinely useful adjunct to resistance exercise in older adults or rehabilitation patients. This hypothesis has not been formally tested in adequately powered clinical trials in elderly or sarcopenic populations. Phase II clinical trials targeting sarcopenic elderly populations, with liposomal PA formulations and tissue-level mTOR activation as endpoints, would represent a scientifically justified next step.
Practical takeaways
- For athletes: Creatine monohydrate, high-quality protein (1.6–2.2 g/kg/day), and leucine-rich meals remain the evidence-based foundation of any hypertrophy strategy. Phosphatidic acid supplementation (750 mg/day of soy-derived PA) has a plausible mechanistic rationale and one positive pilot trial — but the only adequately powered parametric analysis found no significant advantage over placebo. PA may have a modest, real effect that small trials are underpowered to confirm or exclude; it is most interesting as part of a multi-ingredient combination (e.g., alongside leucine, HMB, and vitamin D3 as in the MaxxTOR® protocol), while recognizing that in such combinations the individual contribution of PA cannot be isolated. It is not a priority supplement relative to established ergogenics.
- For clinicians (sports medicine, geriatrics, rehabilitation): The mTOR/PA/mechanotransduction axis is a legitimate and underexplored research target in sarcopenia and anabolic resistance. No PA supplementation protocol currently meets the threshold for clinical recommendation in any patient population. The bioavailability problem is unsolved, the human evidence is limited to young athletes, and prolonged exogenous activation of mTOR carries a non-negligible theoretical risk in the PI3K/Akt/mTOR cancer context that warrants long-term safety monitoring in any future trials. Watch for: phase II trials with liposomal formulations in elderly populations, pharmacokinetic studies with tissue-level endpoints, and adequately powered RCTs using conventional frequentist analysis with pre-registered outcomes.
- The most evidence-consistent recommendation for both groups: Maximize endogenous PA production through mechanically demanding resistance training (high-load compound movements with eccentric emphasis), adequate dietary phosphatidylcholine, and leucine-sufficient protein intake. This approach works through the same mTOR pathway, is free of bioavailability constraints, carries no oncological risk, and has decades of supporting evidence.
Bibliography — 7 verified scientific sources
- Hornberger TA, et al. « The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle. » PNAS. 2006;103(12):4741–4746. PMID: 16537399
- Hornberger TA. « Mechanotransduction and the regulation of mTORC1 signaling in skeletal muscle. » Int J Biochem Cell Biol. 2011;43(9):1267–1276. PMC: PMC3146557
- You JS, et al. « The role of diacylglycerol kinase ζ and phosphatidic acid in the mechanical activation of mTORC1 signaling in skeletal muscle. » J Biol Chem. 2014. DOI: 10.1074/jbc.M113.531392
- Hoffman JR, et al. « Efficacy of phosphatidic acid ingestion on lean body mass, muscle thickness and strength gains. » JISSN. 2012;9(1):47. PMC: PMC3506449
- Gonzalez AM, et al. « Eight weeks of phosphatidic acid supplementation in conjunction with resistance training. » J Sports Sci Med. 2016;15(3):532–539. PMC: PMC4974867
- Escalante G, et al. « The effects of MaxxTOR®. » JISSN. 2016. PMC: PMC4891923
- Wilson JM, et al. « Effects of phosphatidic acid supplementation on muscle accretion, strength and power. » J Int Soc Sports Nutr. 2014;11(1):P21.
NutriCellScience, Mark DOWN — EN edition
Laisser un commentaire